{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:24:26Z","timestamp":1792657466426,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jchf.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:51:12Z","timestamp":1746456672000},"page":"685-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-7464","authenticated-orcid":false,"given":"Jan M.","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-4413","authenticated-orcid":false,"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2025.03.017_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2025.03.017_bib2","author":"Wasfy"},{"key":"10.1016\/j.jchf.2025.03.017_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jchf.2025.03.017_bib4","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2025.03.017_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib7","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy\u2013associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2025.03.017_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.03.017_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural History, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.03.017_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.017_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2025.03.017_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.jchf.2025.03.017_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jchf.2025.03.017_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2025.03.017_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib18","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis\u2013related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ehf2.15091","article-title":"Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: the DIAMOND study","volume":"12","author":"Tini","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.017_bib20","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A\u00a0human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jchf.2025.03.017_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.017_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2025.03.017_bib23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.03.017_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2025.03.017_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jchf.2025.03.017_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506129.2023.2263620","article-title":"Heterogeneous worldwide access and pricing of tafamidis","volume":"31","author":"Wardhere","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2025.03.017_bib27","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.03.017_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/13506129.2023.2167595","article-title":"Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid","volume":"30","author":"Tsai","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2025.03.017_bib29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2024.4467","article-title":"Cardiovascular burden of the V142I transthyretin variant","volume":"331","author":"Selvaraj","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2025.03.017_bib30","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.03.017_bib31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cardfail.2024.07.021","article-title":"Clinical outcomes of chronic intravenous inotropic support in cardiac amyloidosis","volume":"31","author":"Fajardo","year":"2025","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2025.03.017_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2025.03.017_bib33","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/ehf2.13422","article-title":"A\u00a0case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device","volume":"8","author":"Randhawa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.017_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007931","article-title":"Durable mechanical circulatory support in patients with amyloid cardiomyopathy: insights from INTERMACS","volume":"13","author":"Michelis","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.017_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13663","article-title":"Mechanical circulatory support for cardiac amyloidosis","volume":"33","author":"Kittleson","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jchf.2025.03.017_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2025.03.017_bib37","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1097\/TP.0000000000002240","article-title":"Outcomes after cardiac transplant for wild type transthyretin amyloidosis","volume":"102","author":"Rosenbaum","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jchf.2025.03.017_bib38","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex\u00a0vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2025.03.017_bib39","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s10741-021-10209-3","article-title":"State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond","volume":"27","author":"Kumar","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2025.03.017_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.healun.2021.10.007","article-title":"Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies","volume":"41","author":"Griffin","year":"2022","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2025.03.017_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2022.10.012","article-title":"How to identify cardiac amyloidosis patients who might benefit from cardiac transplantation","volume":"11","author":"Ambardekar","year":"2023","journal-title":"JACC Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925002586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925002586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:42:47Z","timestamp":1777628567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925002586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2213177925002586"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.03.017","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}